Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lacnotuzumab
- Development stage
- Phase 2
- Lead developer
- Novartis
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Lacnotuzumab is a humanized IgG1 kappa monoclonal antibody that targets macrophage colony-stimulating factor (M-CSF or CSF1). By binding to and neutralizing CSF1, it inhibits the activation and recruitment of tumor-associated macrophages, which are implicated in tumor growth and immune evasion. Lacnotuzumab was developed primarily for oncology indications including advanced solid tumors such as triple-negative breast cancer (TNBC), pigmented villonodular synovitis (PVNS), giant cell tumor of tendon sheath (TGCT), prostate cancer, gastric cancer, malignant melanoma, bone metastases, and others. It has been studied both as monotherapy and in combination with other agents such as spartalizumab or chemotherapy. The drug was administered intravenously in clinical trials. Development has been discontinued for all known indications.
- Other names
- lacnotuzumabAnti-M-CSF-antibody
02
Targets
CSF1 (Colony-stimulating factor 1)
Beyond the preview
Go deeper on lacnotuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lacnotuzumab.